Opioid-use DisorderNCT04394559
Prevention of Opioid Use Disorder After Surgery
A study testing Discharge Order Sets, Pharmacist-Led Discharge Counseling and Communication and Post-discharge Pain Management Follow-up in people with Opioid-use Disorder and Opioid Dependence, run by Brigham and Women's Hospital at 1 site in United States.
Trial summary
The objective of this study is to design, implement, and pilot test a multi-faceted intervention to support safer opioid prescribing, self-administration, and monitoring and reduce persistent opioid use and opioid use disorder for patients transitioning to the community setting after major orthopedic surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Opioid-use Disorder, Opioid Dependence, Opioid Use
- What is being tested?
- Discharge Order Sets, Pharmacist-Led Discharge Counseling and Communication and Post-discharge Pain Management Follow-up
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 204 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Jul 2021to 1 Jan 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients admitted to orthopedic or neuro-surgical spine services at Brigham and Women's Hospital during the 6 month enrollment period
- English or Spanish speakers
- Patients who are and are not opioid-naïve for 30 days prior to admission based on their verified preadmission medication list and state-wide opioid prescription information.
- Undergo one of several designated orthopedic or spine surgeries, including trauma and arthroplasty surgeries.
- Age 18 or older
- Clinical discharge plan to home or short-term rehabilitation facility.
Who cannot join
- Not pregnant women, prisoners or institutionalized individuals
- Under the age of 18
- Current illicit opioid use.
- Patient is unable to provide informed consent, and has no available proxy
- Plan to be discharged to an acute care facility.
- Patient requires a second surgery or has medical condition requiring opioid use during the 6-month follow-up period (data are censored at time of second surgery).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prevention of Opioid Use Disorder After Surgery: A Pilot and Feasibility Study
The objective of this study is to design, implement, and pilot test a multi-faceted intervention to support safer opioid prescribing, self-administration, and monitoring and reduce persistent opioid use and opioid use disorder for patients transitioning to the community setting after major orthopedic surgery. The multi-faceted intervention includes: 1) communication with outpatient providers and counseling of patients and caregivers at hospital discharge; 2) standardized opioid prescribing discharge order sets for each type of surgery; 3) an outpatient pain management follow-up visit embedded within routine post-operative care for managing pain and opioid use, and 4) a mobile patient-reported outcomes application for assessing pain, function, and possible development of opioid use disorder (OUD). The primary outcome will be persistent opioid use (in the 6 months after surgery) based on state-wide prescription data. Secondary outcomes will include the total morphine-equivalent dose of opioids prescribed at discharge; total post-operative opioids dispensed in the 6 months after surgery; and self-reported opioid misuse, pain and function 90 and 180 days after surgery.
Read the detailed description
In this study, we will enroll patients who are both opioid-naïve and non-naïve who have undergone orthopedic surgery. To minimize contamination and best evaluate implementation, we will conduct a before-after study. The intervention will consist of four main components: 1) pharmacist-led discharge counseling and communication, 2) discharge order sets, 3) post-discharge pain management follow-up visits; and 4) a patient engagement pain management app. The intervention will last for 6 months following hospital discharge. We plan to enroll 270 patients over a 6-month period to demonstrate the feasibility of the intervention and provide reasonable precision on an effect size to inform power calculations on a subsequent larger scale clinical trial. During implementation, we will measure intervention fidelity and conduct qualitative interviews of stakeholders regarding facilitators and barriers to implementation. Throughout the study, we will engage a patient-family advisory council, other stakeholders, and a Steering Committee and Working Group to guide development and refinement of the intervention, execution of the implementation and evaluation plan, and the communication plan.
Specific Aims:
- Aim 1: To design and implement a multi-faceted intervention (MOPP) to minimize persistent post-operative opioid use while providing adequate analgesia in patients who are status post major orthopedic surgery.
- Aim 2: To pilot test and evaluate the efficacy of MOPP on preventing persistent postoperative opioid use while maintaining adequate analgesia and functional status.
- Aim 3: To evaluate the feasibility and the success of implementation of MOPP and identify barriers to and facilitators of implementation by using mixed methods and the Consolidated Framework for Implementation Research (CFIR).
In the first 3 months of the study, patients will be assigned to usual care, including 1) multimodal analgesia after surgery; 2) unit-based pharmacists as available to monitor the appropriateness of inpatient medication orders, including opioids; 3) the standard discharge medication reconciliation module in the electronic health record (EHR) that compares preadmission and current inpatient medications to facilitate writing of safe medication orders; 4) general guidelines to limit the dose and duration of discharge opioids and to council patients about tapering opioids at home and to stop them by 4-6 weeks post-operatively unless instructed otherwise; and 5) standard follow-up in the outpatient orthopedics clinic within a time frame judged to be appropriate by each inpatient team. In months 4-6 of the study, patients will be assigned to the intervention. The intervention, which we will refer to as MOPP, will consist of four complementary components, as explained below. Each of these is in addition to usual care, as described above.
- Pharmacist-Led Discharge Counseling and Communication: Based on previously designed and evaluated interventions, an inpatient pharmacist will visit each intervention patient on two occasions: 1) An initial intake visit to screen for previous barriers to safe medication use, including lack of understanding of medication regimens, non-adherence, previous side effects, prior substance use disorder or current misuse of substances other than opioids, and lack of monitoring; 2) Prior to discharge and after the discharge opioid regimen has been determined, to provide counseling regarding safe medication use after discharge, address any of the barriers identified from the intake visit, and specifically cover several topics related to safe opioid use.
- Discharge Order Sets: One of the challenges to opioid safety following surgery is the large variation in the dose and duration of opioids prescribed at hospital discharge. Therefore, the first step in developing a discharge order set will be generating consensus among the orthopedic surgeons for a recommended dose and duration of opioids for each commonly performed orthopedic surgery. Following this standardization process, we will work with Partners Information Systems to create a discharge order set for all orthopedic patients. It will include embedded decision support where providers can enter the orthopedic surgery type and receive the recommended discharge opioid regimen. Ordering providers will still be able to prescribe doses, frequencies, and durations other than the recommended amount, but the order set will provide a default.
- Post-Discharge Pain Management Follow-Up: We've chosen to utilize a clinical pharmacist trained in the principles of safe opioid use and pain management to serve as the outpatient pain management follow-up clinician. Follow-up will take place in the outpatient orthopedics department so that patients can see this follow-up clinician as part of already scheduled visits with the orthopedic surgeon and staff after returning home. During the initial post-discharge visit, the focus will be on pain control, functional status, use of opioids and other analgesics, and screening for any possible misuse of opioids. Based on this information, the pharmacist will work with the patient's orthopedist on an action plan, including changes to the patient's opioid regimen, plans for tapers or discontinuation, etc. If there are concerns for development of OUD, then proper referrals and communication will be made to the outpatient addiction psychiatry service. Finally, additional office visits and/or follow-up phone calls will be scheduled as needed. We will maintain an electronic registry of all the patients in the intervention arm so the outpatient pharmacist can track all patients who may have been lost to follow-up, readmitted to the hospital, or have concerning opioid orders, and intervene as necessary.
- Patient Engagement Pain Management App: Based on the version already created for patients with chronic opioid use, the app will be designed to collect and communicate patient-reported outcomes regarding pain management after discharge. Using the app, patients will be able to rate their current pain, including its effects on sleep, function, and mood, and whether their pain is improving or getting worse. We also plan to link the app to the patient's currently prescribed analgesic regimen so that patients can quickly record how they are taking their medications (compared with how they are prescribed). Patients will also have the ability to securely communicate with their outpatient pain management pharmacist for concerns or questions. The research staff will check the server daily for 2-way messages and link the data to the electronic medical record. Other modifications, including a Spanish version and changes unique to this post-orthopedic surgery patient population, will be made during the first 9 months of the study period based on user input and pilot testing.
- Conditions
- Opioid-use Disorder, Opioid Dependence, Opioid Use
- Being tested
- Discharge Order Sets, Pharmacist-Led Discharge Counseling and Communication, Post-discharge Pain Management Follow-up, Patient Engagement Pain Management App
- Medical subject headings
- Opioid-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Discharge Order SetsBehavioural
Discharge order sets will be implemented in the electronic health record and will provide surgeons a guideline for a recommended dose and duration of opioids for each commonly performed orthopedic surgery.
Pharmacist-Led Discharge Counseling and CommunicationBehavioural
Two visits by a trained inpatient pharmacist, including an intake visit to determine previous barriers to safe medication use, and a discharge counseling session with patients and caregivers regarding safe and effective opioid use after discharge; pharmacist communication with providers regarding the post-discharge pain management plan.
Post-discharge Pain Management Follow-upBehavioural
An outpatient pharmacist pain management follow-up visit (with additional contact as needed) embedded within routine post-operative care for managing pain and opioid use.
Patient Engagement Pain Management AppBehavioural
A mobile patient-reported outcomes application for assessing pain, function, and possible development of opioid use disorder.
| Study group | Role | What they receive |
|---|---|---|
| Usual care | No intervention | inpatient pharmacists as available; standard discharge orders; standard follow up visit. |
| Intervention | Experimental | Discharge counseling; discharge opioid order set; post-discharge pain management follow up; patient pain management app. Receives: Behavioral: Discharge Order Sets; Behavioral: Pharmacist-Led Discharge Counseling and Communication; Behavioral: Post-discharge Pain Management Follow-up; Behavioral: Patient Engagement Pain Management App |
What is being measured
The primary outcome is the main question the study is designed to answer.
Persistent Opioid Use
From prescription monitoring program (PMP) data, at least one filled opioid prescription 0-90 days after discharge and another 91-180 days after discharge.
Measured: Post intervention: 90 days after discharge
Persistent Opioid Use
From prescription monitoring program (PMP) data, at least one filled opioid prescription 0-90 days after discharge and another 91-180 days after discharge.
Measured: Post intervention: 180 days after discharge
Secondary outcomes (10)
Long-term Opioid Episodes
From prescription monitoring program (PMP), 3 or more opioid prescriptions dispensed at least 21 days apart; a duration of at least 84 days between the first day of the first prescription and the last day of the last prescription; and at least 84 days of opioids supplied.
Measured: 180 days after discharge
Pain Levels Post-Surgery
Brief Pain Inventory (BPI), 0-10 scales in 9 categories.
Measured: 90 days after discharge
Pain Levels Post-Surgery
Brief Pain Inventory (BPI), 0-10 scales in 9 categories.
Measured: 180 days after discharge
Function
Patient-Reported Outcomes Measurement Information System- Pain Interference (PROMIS-PI), 0-5 scales.
Measured: 90 days after discharge
Function
Patient-Reported Outcomes Measurement Information System- Pain Interference (PROMIS-PI), 0-5 scales.
Measured: 180 days after discharge
Risk of Opioid Use Disorder (OUD)
Current Opioid Misuse Measure (COMM), 0-4 scales in 17 items.
Measured: 90 days after discharge
Risk of Opioid Use Disorder (OUD)
Current Opioid Misuse Measure (COMM), 0-4 scales in 17 items.
Measured: 180 days after discharge
Opioid Use on Discharge
From discharge orders, morphine equivalent dose (MED) of the opioids prescribed at discharge using the opioid type, route, dose, maximum frequency, and duration.
Measured: At day 1 at the time of discharge
Total Post-operative Opioid Use
From PMP data, total MED of all opioids prescribed and dispensed during the study period.
Measured: 180 days after discharge
Post-operative Health Care Utilization
From health system administrative data (for utilization within Partners Healthcare) plus patient self-report (for utilization outside Partners). Emergency Department visits and hospital admissions, measured as any health care utilization and number of encounters.
Measured: 180 days after discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2020
- Study start2 Jul 2021
- Primary completion15 Dec 2023 (estimated)
- Study completion1 Jan 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Opioid-use DisorderStudies of the same condition, open and under way.
- More trials run by Brigham and Women's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Single group
- Model description
- Other: 2 arms, before-after study and mixed methods analysis of implementation
- Masking
- None (open label)
- Enrolment
- 204 participants (actual)
Sponsor and investigators
- Lead sponsor
- Brigham and Women's Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Ohio State University
- Responsible party
- Principal investigator, Jeffrey L. Schnipper, MD.,MPH., Brigham and Women's Hospital
- Investigators
- Jeffrey L Schnipper, MD, MPH, Principal investigator, Brigham and Women's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04394559
- Sponsor's protocol ID
- 2020P001387
- Status last verified
- Aug 2023
- First submitted
- 10 May 2020
- Last updated
- 7 Aug 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No specimens will be collected for this study and no identifiable data will be shared with research collaborators outside Partners. Data collected through this study may be used to further research in post-operative opioid use, but all data will be de-identified prior to storage and use by collaborators.
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevention of Opioid Use Disorder After Surgery: A Pilot and Feasibility Study
- ClinicalTrials.gov ID
- NCT04394559
- Acronym / sponsor ID
- 2020P001387
- Conditions
- Opioid-use Disorder, Opioid Dependence, Opioid Use
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 204 participants (actual)
- Lead sponsor
- Brigham and Women's HospitalUniversity, hospital or other
- Collaborators
- Ohio State University
- Study start
- 2 Jul 2021 (actual)
- Primary completion
- 15 Dec 2023 (estimated)
- Study completion
- 1 Jan 2024 (estimated)
- First posted
- 19 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to design, implement, and pilot test a multi-faceted intervention to support safer opioid prescribing, self-administration, and monitoring and reduce persistent opioid use and opioid use disorder for patients transitioning to the community setting after major orthopedic surgery. The multi-faceted intervention includes: 1) communication with outpatient providers and counseling of patients and caregivers at hospital discharge; 2) standardized opioid prescribing discharge order sets for each type of surgery; 3) an outpatient pain management follow-up visit embedded within routine post-operative care for managing pain and opioid use, and 4) a mobile patient-reported outcomes application for assessing pain, function, and possible development of opioid use disorder (OUD). The primary outcome will be persistent opioid use (in the 6 months after surgery) based on state-wide prescription data. Secondary outcomes will include the total morphine-equivalent dose of opioids prescribed at discharge; total post-operative opioids dispensed in the 6 months after surgery; and self-reported opioid misuse, pain and function 90 and 180 days after surgery.
Detailed description
In this study, we will enroll patients who are both opioid-naïve and non-naïve who have undergone orthopedic surgery. To minimize contamination and best evaluate implementation, we will conduct a before-after study. The intervention will consist of four main components: 1) pharmacist-led discharge counseling and communication, 2) discharge order sets, 3) post-discharge pain management follow-up visits; and 4) a patient engagement pain management app. The intervention will last for 6 months following hospital discharge. We plan to enroll 270 patients over a 6-month period to demonstrate the feasibility of the intervention and provide reasonable precision on an effect size to inform power calculations on a subsequent larger scale clinical trial. During implementation, we will measure intervention fidelity and conduct qualitative interviews of stakeholders regarding facilitators and barriers to implementation. Throughout the study, we will engage a patient-family advisory council, other stakeholders, and a Steering Committee and Working Group to guide development and refinement of the intervention, execution of the implementation and evaluation plan, and the communication plan.
Specific Aims:
- Aim 1: To design and implement a multi-faceted intervention (MOPP) to minimize persistent post-operative opioid use while providing adequate analgesia in patients who are status post major orthopedic surgery.
- Aim 2: To pilot test and evaluate the efficacy of MOPP on preventing persistent postoperative opioid use while maintaining adequate analgesia and functional status.
- Aim 3: To evaluate the feasibility and the success of implementation of MOPP and identify barriers to and facilitators of implementation by using mixed methods and the Consolidated Framework for Implementation Research (CFIR).
In the first 3 months of the study, patients will be assigned to usual care, including 1) multimodal analgesia after surgery; 2) unit-based pharmacists as available to monitor the appropriateness of inpatient medication orders, including opioids; 3) the standard discharge medication reconciliation module in the electronic health record (EHR) that compares preadmission and current inpatient medications to facilitate writing of safe medication orders; 4) general guidelines to limit the dose and duration of discharge opioids and to council patients about tapering opioids at home and to stop them by 4-6 weeks post-operatively unless instructed otherwise; and 5) standard follow-up in the outpatient orthopedics clinic within a time frame judged to be appropriate by each inpatient team. In months 4-6 of the study, patients will be assigned to the intervention. The intervention, which we will refer to as MOPP, will consist of four complementary components, as explained below. Each of these is in addition to usual care, as described above.
- Pharmacist-Led Discharge Counseling and Communication: Based on previously designed and evaluated interventions, an inpatient pharmacist will visit each intervention patient on two occasions: 1) An initial intake visit to screen for previous barriers to safe medication use, including lack of understanding of medication regimens, non-adherence, previous side effects, prior substance use disorder or current misuse of substances other than opioids, and lack of monitoring; 2) Prior to discharge and after the discharge opioid regimen has been determined, to provide counseling regarding safe medication use after discharge, address any of the barriers identified from the intake visit, and specifically cover several topics related to safe opioid use.
- Discharge Order Sets: One of the challenges to opioid safety following surgery is the large variation in the dose and duration of opioids prescribed at hospital discharge. Therefore, the first step in developing a discharge order set will be generating consensus among the orthopedic surgeons for a recommended dose and duration of opioids for each commonly performed orthopedic surgery. Following this standardization process, we will work with Partners Information Systems to create a discharge order set for all orthopedic patients. It will include embedded decision support where providers can enter the orthopedic surgery type and receive the recommended discharge opioid regimen. Ordering providers will still be able to prescribe doses, frequencies, and durations other than the recommended amount, but the order set will provide a default.
- Post-Discharge Pain Management Follow-Up: We've chosen to utilize a clinical pharmacist trained in the principles of safe opioid use and pain management to serve as the outpatient pain management follow-up clinician. Follow-up will take place in the outpatient orthopedics department so that patients can see this follow-up clinician as part of already scheduled visits with the orthopedic surgeon and staff after returning home. During the initial post-discharge visit, the focus will be on pain control, functional status, use of opioids and other analgesics, and screening for any possible misuse of opioids. Based on this information, the pharmacist will work with the patient's orthopedist on an action plan, including changes to the patient's opioid regimen, plans for tapers or discontinuation, etc. If there are concerns for development of OUD, then proper referrals and communication will be made to the outpatient addiction psychiatry service. Finally, additional office visits and/or follow-up phone calls will be scheduled as needed. We will maintain an electronic registry of all the patients in the intervention arm so the outpatient pharmacist can track all patients who may have been lost to follow-up, readmitted to the hospital, or have concerning opioid orders, and intervene as necessary.
- Patient Engagement Pain Management App: Based on the version already created for patients with chronic opioid use, the app will be designed to collect and communicate patient-reported outcomes regarding pain management after discharge. Using the app, patients will be able to rate their current pain, including its effects on sleep, function, and mood, and whether their pain is improving or getting worse. We also plan to link the app to the patient's currently prescribed analgesic regimen so that patients can quickly record how they are taking their medications (compared with how they are prescribed). Patients will also have the ability to securely communicate with their outpatient pain management pharmacist for concerns or questions. The research staff will check the server daily for 2-way messages and link the data to the electronic medical record. Other modifications, including a Spanish version and changes unique to this post-orthopedic surgery patient population, will be made during the first 9 months of the study period based on user input and pilot testing.
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Other: 2 arms, before-after study and mixed methods analysis of implementation
| Arm | Type | Receives |
|---|---|---|
| Usual care | No intervention | –inpatient pharmacists as available; standard discharge orders; standard follow up visit. |
| Intervention | Experimental | Behavioral: Discharge Order Sets, Behavioral: Pharmacist-Led Discharge Counseling and Communication, Behavioral: Post-discharge Pain Management Follow-up, Behavioral: Patient Engagement Pain Management AppDischarge counseling; discharge opioid order set; post-discharge pain management follow up; patient pain management app. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adult patients admitted to orthopedic or neuro-surgical spine services at Brigham and Women's Hospital during the 6 month enrollment period
- English or Spanish speakers
- Patients who are and are not opioid-naïve for 30 days prior to admission based on their verified preadmission medication list and state-wide opioid prescription information.
- Undergo one of several designated orthopedic or spine surgeries, including trauma and arthroplasty surgeries.
- Age 18 or older
Key exclusion criteria (6 listed)
- Not pregnant women, prisoners or institutionalized individuals
- Under the age of 18
- Current illicit opioid use.
- Patient is unable to provide informed consent, and has no available proxy
- Plan to be discharged to an acute care facility.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Discharge Order SetsDischarge order sets will be implemented in the electronic health record and will provide surgeons a guideline for a recommended dose and duration of opioids for each commonly performed orthopedic surgery. | Behavioural | Intervention |
| Pharmacist-Led Discharge Counseling and CommunicationTwo visits by a trained inpatient pharmacist, including an intake visit to determine previous barriers to safe medication use, and a discharge counseling session with patients and caregivers regarding safe and effective opioid use after discharge; pharmacist communication with providers regarding the post-discharge pain management plan. | Behavioural | Intervention |
| Post-discharge Pain Management Follow-upAn outpatient pharmacist pain management follow-up visit (with additional contact as needed) embedded within routine post-operative care for managing pain and opioid use. | Behavioural | Intervention |
| Patient Engagement Pain Management AppA mobile patient-reported outcomes application for assessing pain, function, and possible development of opioid use disorder. | Behavioural | Intervention |
Primary outcome
Persistent Opioid Use
Time frame: Post intervention: 90 days after discharge
From prescription monitoring program (PMP) data, at least one filled opioid prescription 0-90 days after discharge and another 91-180 days after discharge.
Persistent Opioid Use
Time frame: Post intervention: 180 days after discharge
From prescription monitoring program (PMP) data, at least one filled opioid prescription 0-90 days after discharge and another 91-180 days after discharge.
10 secondary outcomes
Long-term Opioid Episodes
Time frame: 180 days after discharge
Pain Levels Post-Surgery
Time frame: 90 days after discharge
Pain Levels Post-Surgery
Time frame: 180 days after discharge
Function
Time frame: 90 days after discharge
Function
Time frame: 180 days after discharge
Risk of Opioid Use Disorder (OUD)
Time frame: 90 days after discharge
Risk of Opioid Use Disorder (OUD)
Time frame: 180 days after discharge
Opioid Use on Discharge
Time frame: At day 1 at the time of discharge
Total Post-operative Opioid Use
Time frame: 180 days after discharge
Post-operative Health Care Utilization
Time frame: 180 days after discharge
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2023.
- Individual participant dataSharing planned: No. No specimens will be collected for this study and no identifiable data will be shared with research collaborators outside Partners. Data collected through this study may be used to further research in post-operative opioid use, but all data will be de-identified prior to storage and use by collaborators.
Related trials for Opioid-use Disorder
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Enrolling by invitationObservational study
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Substance Use Disorders (SUDs)
Not yet recruiting
Comprehensive Opioid Management and Breathing During Sleep
Sleep-Disordered Breathing, Chronic Opioid Use
Active, not recruitingPhase 2
Wellcome Leap Psilocybin for OUD
Opioid Use Disorder
Recruiting
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
Opioid Use Disorder, Opioid Misuse
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jeffrey L Schnipper, MD, MPH principal investigator
Brigham and Women's Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Discharge Order Sets, Pharmacist-Led Discharge Counseling and Communication and Post-discharge Pain Management Follow-up in people with Opioid-use Disorder and Opioid Dependence, run by Brigham and Women's Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Persistent Opioid Use (time frame: Post intervention: 90 days after discharge). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2023.